ID: h-da6c36b942
Hypothesis
Direct cystatin C inhibition of tau aggregation
Cystatin C binds tau through its cystatin-like domain, sequestering monomeric tau and preventing β-sheet aggregation.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 7 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Cystatin C binds tau through its cystatin-like domain, sequestering monomeric tau and preventing β-sheet aggregation. This hypothesis has the weakest mechanistic foundation: cystatin C is secreted (extracellular) while tau is predominantly intracellular. The 2005 Co-IP has not been independently replicated in 20+ years. At physiologically relevant concentrations (10-50 nM CSF), any inhibitory effect may be negligible.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Glymphatic Dysfunction<br/>Sleep Disruption and AQP4 Depolarization"]
B["Impaired ISF-CSF Exchange<br/>Perivascular Clearance Failure"]
C["Tau Accumulation<br/>MAPT-Encoded Tau Aggregation"]
D["Tau Seeding and Spreading<br/>Prion-like Trans-neuronal Propagation"]
E["Neurodegeneration<br/>Synaptic Loss and Cognitive Decline"]
F["Glymphatic Enhancement<br/>Sleep Optimization or Norepinephrine Reduction"]
A --> B
B --> C
C --> D
D --> E
F -.->|"restores"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix7 supports3 contradicts
Supports
Biochemical analyses of cystatin-C dimers and cathepsin-B reveals a trypsin-driven feedback mechanism in acute pancreatitis.
Supports
Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration By release of loop anchoring through mutation of his110.
Supports
Structural basis for the biological specificity of cystatin C. Identification of leucine 9 in the N-terminal binding region as a selectivity-conferring residue in the inhibition of mammalian cysteine peptidases.
Supports
Importance of the evolutionarily conserved glycine residue in the N-terminal region of human cystatin C (Gly-11) for cysteine endopeptidase inhibition.
Supports
Structural basis for different inhibitory specificities of human cystatins C and D.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CST3
No curated PDB or AlphaFold mapping for CST3 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CST3/MAPT interaction from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CST3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.6%
Volatility
Medium
0.0227
Events (7d)
2
Price History
▲15.3%💾 Resource Usage
LLM Tokens
11,154
$0.0335
Total Cost
$0.0335
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF full-length human CST3 is overexpressed intracellularly at 3-fold above endogenous levels in HEK293T cells engineered to aggregate tau (FRET-based biosensor line), THEN tau aggregate burden will de | FRET signal reduction of >25% indicating decreased tau aggregation, with cell viability unchanged | — no observation — | pending | 0.05 |
| IF recombinant human CST3 is added at 10-50 nM (physiological CSF concentration) to in vitro Thioflavin-T tau aggregation assays with recombinant MAPT (2N4R), THEN ThT fluorescence will be reduced by | Significant reduction in tau fibril formation with ThT fluorescence decreasing by >30% relative to control | — no observation — | pending | 0.10 |
🔮 Falsifiable Predictions (2)
pendingconf 10%
IF recombinant human CST3 is added at 10-50 nM (physiological CSF concentration) to in vitro Thioflavin-T tau aggregation assays with recombinant MAPT (2N4R), THEN ThT fluorescence will be reduced by >30% compared to vehicle control within 48 hours.
Predicted outcome: Significant reduction in tau fibril formation with ThT fluorescence decreasing by >30% relative to control
Falsification: No significant reduction in ThT fluorescence (<20% change) or ThT signal unchanged/increased after CST3 treatment
pendingconf 5%
IF full-length human CST3 is overexpressed intracellularly at 3-fold above endogenous levels in HEK293T cells engineered to aggregate tau (FRET-based biosensor line), THEN tau aggregate burden will decrease by >25% within 72 hours post-transfection.
Predicted outcome: FRET signal reduction of >25% indicating decreased tau aggregation, with cell viability unchanged
Falsification: FRET signal unchanged or increased (<10% change), or filter trap assay shows no reduction in insoluble tau; no change in phosphorylation state (AT8, AT180)
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.